



123  
AF/1615  
PATENT  
Customer No. 22,852  
Attorney Docket No. 05725.0213-00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: )  
)  
Paolo GIACOMONI ) Group Art Unit: 1615  
)  
Application No.: 08/894,788 ) Examiner: L. Channavajjala  
)  
Filed: February 9, 2000 )  
)  
For: NITRIC OXIDE SYNTHASE ) Confirmation No.: 9346  
INHIBITORS )

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(d)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(d), Applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed after a Final Office Action, but before payment of the issue fee and is accompanied by a fee of \$180.00 as specified under § 1.17(p) and a certification as specified under § 1.97(e).

The undersigned, based upon diligent inquiry, informs the Patent Office that each document listed in this Information Disclosure Statement was first cited in a communication from the European Patent Office in a counterpart foreign application and is being filed within three months of the mailing date of that communication.

Copies of the listed documents, including any copending patent applications, are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.


Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: May 17, 2004

By:   
Michele C. Bosch  
Reg. No. 40,524

# INFORMATION DISCLOSURE CITATION

Atty. Docket No.	05725.0213-00	Appln. No.	08/894,788
Applicant	Paolo GIACOMONI		
Filing Date	February 9, 2000	Group:	1615



## U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
	5,360,925	11/1/1994	Chabrier de Lassauniere et al.			

## FOREIGN PATENT DOCUMENTS

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or N
2 240 041 A	7/24/1991	Great Britain			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Armando Ialenti et al., "Modulation of acute inflammation by endogenous nitric oxide," <i>European Journal of Pharmacology</i> , 211 (1992) pgs. 177-182.
Unofficial translated copy of Opposition to European Patent No. 0 812 184 (EP counterpart of U.S. Appln. No. 08/894,788)

Examiner	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	
Form PTO 1449	Patent and Trademark Office - U.S. Department of Commerce